Blair Leavitt - Publications

Affiliations: 
University of British Columbia, Vancouver, Vancouver, BC, Canada 

147 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, et al. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. Jama. 316: 40-50. PMID 27380342 DOI: 10.1001/jama.2016.8655  1
2016 Labuschagne I, Cassidy AM, Scahill RI, Johnson EB, Rees E, O'Regan A, Queller S, Frost C, Leavitt BR, Dürr A, Roos R, Owen G, Borowsky B, Tabrizi SJ, Stout JC, et al. Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease. Journal of the International Neuropsychological Society : Jins. 1-14. PMID 27211109 DOI: 10.1017/S1355617716000321  1
2016 Wiecki TV, Antoniades CA, Stevenson A, Kennard C, Borowsky B, Owen G, Leavitt B, Roos R, Durr A, Tabrizi SJ, Frank MJ. A Computational Cognitive Biomarker for Early-Stage Huntington's Disease. Plos One. 11: e0148409. PMID 26872129 DOI: 10.1371/journal.pone.0148409  1
2016 Keogh R, Frost C, Owen G, Daniel RM, Langbehn DR, Leavitt B, Durr A, Roos RA, Landwehrmeyer GB, Reilmann R, Borowsky B, Stout J, Craufurd D, Tabrizi SJ. Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance. Plos Currents. 8. PMID 26819833 DOI: 10.1371/currents.hd.8060298fac1801b01ccea6acc00f97cb  1
2015 Petkau TL, Hill A, Leavitt BR. Core neuropathological abnormalities in progranulin-deficient mice are penetrant on multiple genetic backgrounds. Neuroscience. 315: 175-195. PMID 26701296 DOI: 10.1016/j.neuroscience.2015.12.006  1
2015 Minkova L, Scheller E, Peter J, Abdulkadir A, Kaller CP, Roos RA, Durr A, Leavitt BR, Tabrizi SJ, Klöppel S. Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling. Frontiers in Human Neuroscience. 9: 634. PMID 26635585 DOI: 10.3389/fnhum.2015.00634  1
2015 Johnson EB, Rees EM, Labuschagne I, Durr A, Leavitt BR, Roos RA, Reilmann R, Johnson H, Hobbs NZ, Langbehn DR, Stout JC, Tabrizi SJ, Scahill RI. The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. Neuropsychologia. PMID 26519555 DOI: 10.1016/j.neuropsychologia.2015.10.033  1
2015 Minkova L, Eickhoff SB, Abdulkadir A, Kaller CP, Peter J, Scheller E, Lahr J, Roos RA, Durr A, Leavitt BR, Tabrizi SJ, Klöppel S. Large-scale brain network abnormalities in Huntington's disease revealed by structural covariance. Human Brain Mapping. PMID 26453902 DOI: 10.1002/hbm.23014  1
2015 Wagner L, Wolf R, Zeitschel U, Rossner S, Petersén Å, Leavitt BR, Kästner F, Rothermundt M, Gärtner UT, Gündel D, Schlenzig D, Frerker N, Schade J, Manhart S, Rahfeld JU, et al. Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery. Journal of Neurochemistry. PMID 26442809 DOI: 10.1111/jnc.13378  1
2015 Howard AK, Krishnamoorthy A, Leavitt BR, Raymond LA, Weissman CR. Treatment of Huntington Disease and Comorbid Trichotillomania With Aripiprazole. The Journal of Neuropsychiatry and Clinical Neurosciences. 27: e211-2. PMID 26222972 DOI: 10.1176/appi.neuropsych.14090232  1
2015 Southwell AL, Smith SE, Davis TR, Caron NS, Villanueva EB, Xie Y, Collins JA, Li Ye M, Sturrock A, Leavitt BR, Schrum AG, Hayden MR. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Scientific Reports. 5: 12166. PMID 26174131 DOI: 10.1038/srep12166  1
2015 Jan A, Karasinska JM, Kang MH, de Haan W, Ruddle P, Kaur A, Connolly C, Leavitt BR, Sorensen PH, Hayden MR. Direct intracerebral delivery of a miR-33 antisense oligonucelotide into mouse brain increases brain ABCA1 expression. Neuroscience Letters. 598: 66-72. PMID 25957561 DOI: 10.1016/j.neulet.2015.05.007  1
2015 Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JR, Zetterberg H, Leavitt BR, Kuhn R, Tabrizi SJ, Macdonald D, Weiss A. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. The Journal of Clinical Investigation. 125: 1979-86. PMID 25844897 DOI: 10.1172/JCI80743  1
2015 Callaghan J, Stopford C, Arran N, Boisse MF, Coleman A, Santos RD, Dumas EM, Hart EP, Justo D, Owen G, Read J, Say MJ, Durr A, Leavitt BR, Roos RA, et al. Reliability and factor structure of the Short Problem Behaviors Assessment for Huntington's disease (PBA-s) in the TRACK-HD and REGISTRY studies. The Journal of Neuropsychiatry and Clinical Neurosciences. 27: 59-64. PMID 25716488 DOI: 10.1176/appi.neuropsych.13070169  1
2015 Sturrock A, Laule C, Wyper K, Milner RA, Decolongon J, Dar Santos R, Coleman AJ, Carter K, Creighton S, Bechtel N, Bohlen S, Reilmann R, Johnson HJ, Hayden MR, Tabrizi SJ, ... ... Leavitt BR, et al. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 393-401. PMID 25690257 DOI: 10.1002/mds.26118  1
2015 Angus D, Herd C, Stone C, Stout J, Wieler M, Reilmann R, Ritchie CW, Dorsey ER, Helles K, Kayson E, Oakes D, Rosas HD, Vaughan C, Panegyres PK, Ames D, ... ... Leavitt BR, et al. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: A phase 2, randomised, double-blind, placebo-controlled trial The Lancet Neurology. 14: 39-47. PMID 25467848 DOI: 10.1016/S1474-4422(14)70262-5  1
2015 De Souza RA, Leavitt BR. Neurobiology of Huntington's Disease. Current Topics in Behavioral Neurosciences. 22: 81-100. PMID 25205327 DOI: 10.1007/7854_2014_353  1
2015 Becanovic K, Nørremølle A, Neal SJ, Kay C, Collins JA, Arenillas D, Lilja T, Gaudenzi G, Manoharan S, Doty CN, Beck J, Lahiri N, Portales-Casamar E, Warby SC, Connolly C, ... ... Leavitt BR, et al. A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease Nature Neuroscience. 18: 807-816. DOI: 10.1038/nn.4014  1
2015 Jan A, Karasinska JM, Kang MH, Haan Wd, Ruddle P, Kaur A, Connolly C, Leavitt BR, Sorensen PH, Hayden MR. Corrigendum to "Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression'' [Neuroscience Letters 598 (2015) 66-72] Neuroscience Letters. 602: 172. DOI: 10.1016/j.neulet.2015.06.047  1
2015 Klöppel S, Gregory S, Scheller E, Minkova L, Razi A, Durr A, Roos RAC, Leavitt BR, Papoutsi M, Landwehrmeyer GB, Reilmann R, Borowsky B, Johnson H, Mills JA, Owen G, et al. Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study Ebiomedicine. DOI: 10.1016/j.ebiom.2015.08.002  1
2014 Träger U, Andre R, Magnusson-Lind A, Miller JR, Connolly C, Weiss A, Grueninger S, Silajdži? E, Smith DL, Leavitt BR, Bates GP, Björkqvist M, Tabrizi SJ. Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiology of Disease. 73: 388-398. PMID 25447230 DOI: 10.1016/j.nbd.2014.10.012  1
2014 Reilmann R, Leavitt BR, Ross CA. Huntington's disease: a field on the move. Introduction. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1333-4. PMID 25164859 DOI: 10.1002/mds.26017  1
2014 Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington's disease based on natural history. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1335-41. PMID 25164527 DOI: 10.1002/mds.26011  1
2014 Jones R, Stout JC, Labuschagne I, Say M, Justo D, Coleman A, Dumas EM, Hart E, Owen G, Durr A, Leavitt BR, Roos R, O'Regan A, Langbehn D, Tabrizi SJ, et al. The potential of composite cognitive scores for tracking progression in Huntington's disease. Journal of Huntington's Disease. 3: 197-207. PMID 25062862 DOI: 10.3233/JHD-140101  1
2014 Plecash AR, Leavitt BR. Aquatherapy for neurodegenerative disorders. Journal of Huntington's Disease. 3: 5-11. PMID 25062761 DOI: 10.3233/JHD-140010  1
2014 Petkau TL, Leavitt BR. Progranulin in neurodegenerative disease. Trends in Neurosciences. 37: 388-98. PMID 24800652 DOI: 10.1016/j.tins.2014.04.003  1
2014 Wang SP, Wu JW, Bourdages H, Lefebvre JF, Casavant S, Leavitt BR, Labuda D, Trasler J, Smith CE, Hermo L, Mitchell GA. The catalytic function of hormone-sensitive lipase is essential for fertility in male mice. Endocrinology. 155: 3047-53. PMID 24797631 DOI: 10.1210/en.2014-1031  1
2014 Kostro D, Abdulkadir A, Durr A, Roos R, Leavitt BR, Johnson H, Cash D, Tabrizi SJ, Scahill RI, Ronneberger O, Klöppel S. Correction of inter-scanner and within-subject variance in structural MRI based automated diagnosing. Neuroimage. 98: 405-15. PMID 24791746 DOI: 10.1016/j.neuroimage.2014.04.057  1
2014 Muller M, Leavitt BR. Iron dysregulation in Huntington's disease. Journal of Neurochemistry. 130: 328-50. PMID 24717009 DOI: 10.1111/jnc.12739  1
2014 Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews. Neurology. 10: 204-16. PMID 24614516 DOI: 10.1038/nrneurol.2014.24  1
2014 Saft C, Leavitt BR, Epplen JT. Clinical utility gene card for: Huntington's disease. European Journal of Human Genetics : Ejhg. 22. PMID 24105375 DOI: 10.1038/ejhg.2013.206  1
2014 Ehrnhoefer DE, Skotte NH, Ladha S, Nguyen YT, Qiu X, Deng Y, Huynh KT, Engemann S, Nielsen SM, Becanovic K, Leavitt BR, Hasholt L, Hayden MR. p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Human Molecular Genetics. 23: 717-29. PMID 24070868 DOI: 10.1093/hmg/ddt458  1
2014 Mazarei G, Leavitt BR. Murine Models of HD Movement Disorders: Genetics and Models: Second Edition. 533-546. DOI: 10.1016/B978-0-12-405195-9.00031-7  1
2013 Read J, Jones R, Owen G, Leavitt BR, Coleman A, Roos RA, Dumas EM, Durr A, Justo D, Say M, Stout JC, Tabrizi SJ, Craufurd D. Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners. Journal of Huntington's Disease. 2: 159-75. PMID 25063513 DOI: 10.3233/JHD-130051  1
2013 Crawford HE, Hobbs NZ, Keogh R, Langbehn DR, Frost C, Johnson H, Landwehrmeyer B, Reilmann R, Craufurd D, Stout JC, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Scahill RI, et al. Corpus callosal atrophy in premanifest and early Huntington's disease. Journal of Huntington's Disease. 2: 517-26. PMID 25062736 DOI: 10.3233/JHD-130077  1
2013 Leavitt BR, Thompson LM. We are pleased to introduce this next volume of the Journal of Huntington's Disease. Introduction. Journal of Huntington's Disease. 2: 1. PMID 25057106 DOI: 10.3233/JHD-130003  1
2013 Park KH, Franciosi S, Leavitt BR. Postnatal muscle modification by myogenic factors modulates neuropathology and survival in an ALS mouse model. Nature Communications. 4: 2906. PMID 24346342 DOI: 10.1038/ncomms3906  1
2013 Franciosi S, Shim Y, Lau M, Hayden MR, Leavitt BR. A systematic review and meta-analysis of clinical variables used in Huntington disease research. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1987-94. PMID 24142393 DOI: 10.1002/mds.25663  1
2013 Mazarei G, Budac DP, Lu G, Lee H, Möller T, Leavitt BR. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain. Experimental Neurology. 249: 144-8. PMID 23994717 DOI: 10.1016/j.expneurol.2013.08.007  1
2013 Zhu S, Tai C, Petkau TL, Zhang S, Liao C, Dong Z, Wen W, Chang Q, Tian Wang Y, MacVicar BA, Leavitt BR, Jia W, Cynader MS. Progranulin promotes activation of microglia/macrophage after pilocarpine-induced status epilepticus. Brain Research. 1530: 54-65. PMID 23887054 DOI: 10.1016/j.brainres.2013.07.023  1
2013 Mazarei G, Budac DP, Lu G, Adomat H, Tomlinson Guns ES, Möller T, Leavitt BR. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. Journal of Neurochemistry. 127: 852-67. PMID 23786539 DOI: 10.1111/jnc.12350  1
2013 Petkau TL, Zhu S, Lu G, Fernando S, Cynader M, Leavitt BR. Sensitivity to neurotoxic stress is not increased in progranulin-deficient mice. Neurobiology of Aging. 34: 2548-50. PMID 23702345 DOI: 10.1016/j.neurobiolaging.2013.04.019  1
2013 Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. The Lancet. Neurology. 12: 637-49. PMID 23664844 DOI: 10.1016/S1474-4422(13)70088-7  1
2013 Borowsky B, Warner J, Leavitt BR, Tabrizi SJ, Roos RA, Durr A, Becker C, Sampaio C, Tobin AJ, Schulman H. 8OHdG is not a biomarker for Huntington disease state or progression. Neurology. 80: 1934-41. PMID 23616162 DOI: 10.1212/WNL.0b013e318293e1a1  1
2013 . A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1407-15. PMID 23450660 DOI: 10.1002/mds.25362  1
2013 Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 189-98. PMID 23062850 DOI: 10.1016/j.jalz.2012.03.003  1
2013 Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, et al. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 176-88. PMID 23043900 DOI: 10.1016/j.jalz.2012.03.002  1
2013 Scahill RI, Hobbs NZ, Say MJ, Bechtel N, Henley SM, Hyare H, Langbehn DR, Jones R, Leavitt BR, Roos RA, Durr A, Johnson H, Lehéricy S, Craufurd D, Kennard C, et al. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Human Brain Mapping. 34: 519-29. PMID 22102212 DOI: 10.1002/hbm.21449  1
2012 Dumas EM, Say MJ, Jones R, Labuschagne I, O'Regan AM, Hart EP, van den Bogaard SJ, Queller S, Justo D, Coleman A, Dar Santos RC, Dürr A, Leavitt BR, Tabrizi SJ, Roos RA, et al. Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease. Journal of Huntington's Disease. 1: 97-106. PMID 25063192 DOI: 10.3233/JHD-2012-120010  1
2012 Leavitt BR, Thompson LM. Journal of Huntington's Disease. Journal of Huntington's Disease. 1: 1. PMID 25056612 DOI: 10.3233/JHD-2012-120001  1
2012 Park KH, Lu G, Fan J, Raymond LA, Leavitt BR. Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons. Journal of Huntington's Disease. 1. PMID 24353748 DOI: 10.3233/JHD-2012-129000  1
2012 Stout JC, Jones R, Labuschagne I, O'Regan AM, Say MJ, Dumas EM, Queller S, Justo D, Santos RD, Coleman A, Hart EP, Dürr A, Leavitt BR, Roos RA, Langbehn DR, et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 83: 687-94. PMID 22566599 DOI: 10.1136/jnnp-2011-301940  1
2012 Tang B, Becanovic K, Desplats PA, Spencer B, Hill AM, Connolly C, Masliah E, Leavitt BR, Thomas EA. Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. Human Molecular Genetics. 21: 3097-111. PMID 22492998 DOI: 10.1093/hmg/dds132  1
2012 Harrington DL, Smith MM, Zhang Y, Carlozzi NE, Paulsen JS. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. Journal of Neurology, Neurosurgery, and Psychiatry. 83: 612-9. PMID 22451099 DOI: 10.1136/jnnp-2011-301732  1
2012 Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS. 8OHdG as a marker for Huntington disease progression. Neurobiology of Disease. 46: 625-34. PMID 22414782 DOI: 10.1016/j.nbd.2012.02.012  1
2012 Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. The Lancet. Neurology. 11: 42-53. PMID 22137354 DOI: 10.1016/S1474-4422(11)70263-0  1
2012 Petkau TL, Neal SJ, Milnerwood A, Mew A, Hill AM, Orban P, Gregg J, Lu G, Feldman HH, Mackenzie IR, Raymond LA, Leavitt BR. Synaptic dysfunction in progranulin-deficient mice. Neurobiology of Disease. 45: 711-22. PMID 22062772 DOI: 10.1016/j.nbd.2011.10.016  1
2012 Franciosi S, Ryu JK, Shim Y, Hill A, Connolly C, Hayden MR, McLarnon JG, Leavitt BR. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 45: 438-49. PMID 21946335 DOI: 10.1016/j.nbd.2011.09.003  1
2012 Connolly C, Hill A, Leavitt BR. Microglia in huntington disease Microglia: Biology, Functions and Roles in Disease. 253-271.  1
2011 Sivananthan SN, Leavitt BR. Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice. Neurobiology of Aging. 32: 2326.e1-4. PMID 21741126 DOI: 10.1016/j.neurobiolaging.2011.05.020  1
2011 Fotovati A, Abu-Ali S, Wang PS, Deleyrolle LP, Lee C, Triscott J, Chen JY, Franciosi S, Nakamura Y, Sugita Y, Uchiumi T, Kuwano M, Leavitt BR, Singh SK, Jury A, et al. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Research. 71: 5569-78. PMID 21730024 DOI: 10.1158/0008-5472.CAN-10-2805  1
2011 Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington's disease. The Lancet. Neurology. 10: 573-90. PMID 21601164 DOI: 10.1016/S1474-4422(11)70070-9  1
2011 Hobbs NZ, Pedrick AV, Say MJ, Frost C, Dar Santos R, Coleman A, Sturrock A, Craufurd D, Stout JC, Leavitt BR, Barnes J, Tabrizi SJ, Scahill RI. The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1684-90. PMID 21557312 DOI: 10.1002/mds.23747  1
2011 Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. The Lancet. Neurology. 10: 31-42. PMID 21130037 DOI: 10.1016/S1474-4422(10)70276-3  1
2010 Bechtel N, Scahill RI, Rosas HD, Acharya T, van den Bogaard SJ, Jauffret C, Say MJ, Sturrock A, Johnson H, Onorato CE, Salat DH, Durr A, Leavitt BR, Roos RA, Landwehrmeyer GB, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology. 75: 2150-60. PMID 21068430 DOI: 10.1212/WNL.0b013e3182020123  1
2010 Sturrock A, Laule C, Decolongon J, Dar Santos R, Coleman AJ, Creighton S, Bechtel N, Reilmann R, Hayden MR, Tabrizi SJ, Mackay AL, Leavitt BR. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology. 75: 1702-10. PMID 21060093 DOI: 10.1212/WNL.0b013e3181fc27e4  1
2010 Metzler M, Gan L, Mazarei G, Graham RK, Liu L, Bissada N, Lu G, Leavitt BR, Hayden MR. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 14318-29. PMID 20980587 DOI: 10.1523/JNEUROSCI.1589-10.2010  1
2010 Sturrock A, Leavitt BR. The clinical and genetic features of Huntington disease. Journal of Geriatric Psychiatry and Neurology. 23: 243-59. PMID 20923757 DOI: 10.1177/0891988710383573  1
2010 Petkau TL, Neal SJ, Orban PC, MacDonald JL, Hill AM, Lu G, Feldman HH, Mackenzie IR, Leavitt BR. Progranulin expression in the developing and adult murine brain. The Journal of Comparative Neurology. 518: 3931-47. PMID 20737593 DOI: 10.1002/cne.22430  1
2010 Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Human Molecular Genetics. 19: 1528-38. PMID 20097678 DOI: 10.1093/hmg/ddq026  1
2010 Becanovic K, Pouladi MA, Lim RS, Kuhn A, Pavlidis P, Luthi-Carter R, Hayden MR, Leavitt BR. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Human Molecular Genetics. 19: 1438-52. PMID 20089533 DOI: 10.1093/hmg/ddq018  1
2010 Mazarei G, Neal SJ, Becanovic K, Luthi-Carter R, Simpson EM, Leavitt BR. Expression analysis of novel striatal-enriched genes in Huntington disease. Human Molecular Genetics. 19: 609-22. PMID 19934114 DOI: 10.1093/hmg/ddp527  1
2009 Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. The Lancet. Neurology. 8: 791-801. PMID 19646924 DOI: 10.1016/S1474-4422(09)70170-X  1
2009 Yeretssian G, Doiron K, Shao W, Leavitt BR, Hayden MR, Nicholson DW, Saleh M. Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection. Proceedings of the National Academy of Sciences of the United States of America. 106: 9016-20. PMID 19447924 DOI: 10.1073/pnas.0813362106  1
2009 Joshi PR, Wu NP, André VM, Cummings DM, Cepeda C, Joyce JA, Carroll JB, Leavitt BR, Hayden MR, Levine MS, Bamford NS. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 2414-27. PMID 19244517 DOI: 10.1523/JNEUROSCI.5687-08.2009  1
2009 Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, Wu NP, Figueroa BE, Metzler M, André VM, Slow EJ, Raymond L, Friedlander R, Levine MS, Leavitt BR, Hayden MR. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 2193-204. PMID 19228972 DOI: 10.1523/JNEUROSCI.5473-08.2009  1
2009 Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P. Tetrabenazine. Nature Reviews. Drug Discovery. 8: 17-8. PMID 19116624 DOI: 10.1038/nrd2784  1
2009 Fang Q, Strand A, Law W, Faca VM, Fitzgibbon MP, Hamel N, Houle B, Liu X, May DH, Poschmann G, Roy L, Stühler K, Ying W, Zhang J, Zheng Z, ... ... Leavitt BR, et al. Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Molecular & Cellular Proteomics : McP. 8: 451-66. PMID 18984577 DOI: 10.1074/mcp.M800231-MCP200  1
2009 Sturrock A, Leavitt BR. Murine models of Huntington disease Future Neurology. 4: 617-638. DOI: 10.2217/fnl.09.34  1
2008 Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, ... ... Leavitt BR, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. The Journal of Experimental Medicine. 205: 1869-77. PMID 18625748 DOI: 10.1084/jem.20080178  1
2008 Semaka A, Warby S, Leavitt BR, Hayden MR. Re: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 1794-5; author reply. PMID 18548612 DOI: 10.1002/mds.21820  1
2007 Orban P, Devon RS, Hayden MR, Leavitt BR. Chapter 15 Juvenile amyotrophic lateral sclerosis. Handbook of Clinical Neurology. 82: 301-12. PMID 18808900 DOI: 10.1016/S0072-9752(07)80018-2  1
2007 Björkqvist M, Leavitt BR, Nielsen JE, Landwehrmeyer B, Ecker D, Mulder H, Brundin P, Petersén A. Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 1952-4. PMID 17722045 DOI: 10.1002/mds.21447  1
2007 Wong D, Dwinnel M, Schulzer M, Nimmo M, Leavitt BR, Spacey SD. Ataxia and the role of antigliadin antibodies. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 34: 193-6. PMID 17598597  1
2007 Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, Petersén A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. Journal of Proteome Research. 6: 2833-40. PMID 17552550 DOI: 10.1021/pr0700753  1
2007 Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics. 16: 1845-61. PMID 17519223 DOI: 10.1093/hmg/ddm133  1
2007 Butland SL, Devon RS, Huang Y, Mead CL, Meynert AM, Neal SJ, Lee SS, Wilkinson A, Yang GS, Yuen MM, Hayden MR, Holt RA, Leavitt BR, Ouellette BF. CAG-encoded polyglutamine length polymorphism in the human genome. Bmc Genomics. 8: 126. PMID 17519034 DOI: 10.1186/1471-2164-8-126  1
2007 Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersén A, Björkqvist M, Muir C, Mackenzie IR, Hammond GL, Vogl AW, Hayden MR, Leavitt BR. Testicular degeneration in Huntington disease. Neurobiology of Disease. 26: 512-20. PMID 17433700 DOI: 10.1016/j.nbd.2007.01.006  1
2007 Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J, Graham RK, Leavitt BR, Hayden MR. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiology of Disease. 26: 189-200. PMID 17276692 DOI: 10.1016/j.nbd.2006.12.010  1
2006 Van Raamsdonk JM, Pearson J, Murphy Z, Hayden MR, Leavitt BR. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. Bmc Neuroscience. 7: 80. PMID 17147801 DOI: 10.1186/1471-2202-7-80  1
2006 Zhang Y, Leavitt BR, van Raamsdonk JM, Dragatsis I, Goldowitz D, MacDonald ME, Hayden MR, Friedlander RM. Huntingtin inhibits caspase-3 activation. The Embo Journal. 25: 5896-906. PMID 17124493 DOI: 10.1038/sj.emboj.7601445  1
2006 Leavitt BR, Hayden MR. Is tetrabenazine safe and effective for suppressing chorea in Huntington's disease? Nature Clinical Practice. Neurology. 2: 536-7. PMID 16990826 DOI: 10.1038/ncpneuro0299  1
2006 Mackenzie IR, Butland SL, Devon RS, Dwosh E, Feldman H, Lindholm C, Neal SJ, Ouellette BF, Leavitt BR. Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease. Bmc Neurology. 6: 32. PMID 16945149 DOI: 10.1186/1471-2377-6-32  1
2006 Björkqvist M, Petersén A, Nielsen J, Ecker D, Mulder H, Hayden MR, Landwehrmeyer B, Brundin P, Leavitt BR. Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. Clinical Genetics. 70: 78-9. PMID 16813610 DOI: 10.1111/j.1399-0004.2006.00636.x  1
2006 Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, Warby SC, Doty CN, Roy S, Wellington CL, Leavitt BR, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 125: 1179-91. PMID 16777606 DOI: 10.1016/j.cell.2006.04.026  1
2006 Devon RS, Orban PC, Gerrow K, Barbieri MA, Schwab C, Cao LP, Helm JR, Bissada N, Cruz-Aguado R, Davidson TL, Witmer J, Metzler M, Lam CK, Tetzlaff W, Simpson EM, ... ... Leavitt BR, et al. Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proceedings of the National Academy of Sciences of the United States of America. 103: 9595-600. PMID 16769894 DOI: 10.1073/pnas.0510197103  1
2006 Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiology of Disease. 23: 190-7. PMID 16697652 DOI: 10.1016/j.nbd.2006.02.011  1
2006 Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR. Body weight is modulated by levels of full-length huntingtin. Human Molecular Genetics. 15: 1513-23. PMID 16571604 DOI: 10.1093/hmg/ddl072  1
2006 Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, Wellington CL, Raymond LA, Hayden MR. Wild-type huntingtin protects neurons from excitotoxicity. Journal of Neurochemistry. 96: 1121-9. PMID 16417581 DOI: 10.1111/j.1471-4159.2005.03605.x  1
2006 Graham RK, Slow EJ, Deng Y, Bissada N, Lu G, Pearson J, Shehadeh J, Leavitt BR, Raymond LA, Hayden MR. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiology of Disease. 21: 444-55. PMID 16230019 DOI: 10.1016/j.nbd.2005.08.007  1
2006 Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiology of Disease. 21: 392-403. PMID 16165367 DOI: 10.1016/j.nbd.2005.08.001  1
2006 Becanovic K, Leavitt BR. Age-related dysfunction of the cellular powerplants Clinical Genetics. 70: 383-385. DOI: 10.1111/j.1399-0004.2006.0699_2.x  1
2006 Mazarei G, Wagner LA, Leavitt BR. Pathogenesis in SCA8 is a two-way street Clinical Genetics. 70: 382-383. DOI: 10.1111/j.1399-0004.2006.0699_1.x  1
2006 Neal SJ, Leavitt BR. Bad neighbors cause dementia; a second 17q21-linked gene responsible for frontotemporal dementia Clinical Genetics. 70: 385-387. DOI: 10.1111/j.1399-0004.2006.00699_3.x  1
2005 Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Human Molecular Genetics. 14: 3823-35. PMID 16278236 DOI: 10.1093/hmg/ddi407  1
2005 Van Raamsdonk JM, Pearson J, Bailey CD, Rogers DA, Johnson GV, Hayden MR, Leavitt BR. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. Journal of Neurochemistry. 95: 210-20. PMID 16181425 DOI: 10.1111/j.1471-4159.2005.03357.x  1
2005 Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D, Ross CA, Ferrante RJ, Beal MF. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. Journal of Neurochemistry. 95: 553-62. PMID 16135087 DOI: 10.1111/j.1471-4159.2005.03411.x  1
2005 Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, Honer WG, Hayden MR, Leavitt BR. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Experimental Neurology. 196: 266-72. PMID 16129433 DOI: 10.1016/j.expneurol.2005.07.021  1
2005 Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proceedings of the National Academy of Sciences of the United States of America. 102: 11402-7. PMID 16076956 DOI: 10.1073/pnas.0503634102  1
2005 Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 65: 286-92. PMID 16043801 DOI: 10.1212/01.wnl.0000169025.09670.6d  1
2005 Pinto JT, Van Raamsdonk JM, Leavitt BR, Hayden MR, Jeitner TM, Thaler HT, Krasnikov BF, Cooper AJ. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. Journal of Neurochemistry. 94: 1087-101. PMID 15992377 DOI: 10.1111/j.1471-4159.2005.03255.x  1
2005 Missirlis PI, Mead CL, Butland SL, Ouellette BF, Devon RS, Leavitt BR, Holt RA. Satellog: a database for the identification and prioritization of satellite repeats in disease association studies. Bmc Bioinformatics. 6: 145. PMID 15949044 DOI: 10.1186/1471-2105-6-145  1
2005 Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 4169-80. PMID 15843620 DOI: 10.1523/JNEUROSCI.0590-05.2005  1
2005 Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR, Leavitt BR. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Human Molecular Genetics. 14: 1379-92. PMID 15829505 DOI: 10.1093/hmg/ddi147  1
2005 Devon RS, Schwab C, Topp JD, Orban PC, Yang YZ, Pape TD, Helm JR, Davidson TL, Rogers DA, Gros-Louis F, Rouleau G, Horazdovsky BF, Leavitt BR, Hayden MR. Cross-species characterization of the ALS2 gene and analysis of its pattern of expression in development and adulthood. Neurobiology of Disease. 18: 243-57. PMID 15686953 DOI: 10.1016/j.nbd.2004.10.002  1
2005 Sivananthan SN, Leavitt BR. Got NGF? Promising gene therapy results in Alzheimer's disease Clinical Genetics. 68: 194-196. DOI: 10.1111/j.1399-0004.2005.0494b.x  1
2005 Pearson J, Leavitt BR. TB or not TB? Ipr1 answers the question Clinical Genetics. 68: 193-198. DOI: 10.1111/j.1399-0004.2005.0494a.x  1
2005 Yamashita DT, Leavitt BR. Silent, but deadly: Epigenetic control of ID4 in leukemia Clinical Genetics. 68: 196. DOI: 10.1111/j.1399-0004.2005.00494c.x  1
2005 Van Raamsdonk JM, Hayden MR, Leavitt BR. Experimental models of Huntington's disease Drug Discovery Today: Disease Models. 2: 291-297. DOI: 10.1016/j.ddmod.2005.11.010  1
2004 Hagerman RJ, Leavitt BR, Farzin F, Jacquemont S, Greco CM, Brunberg JA, Tassone F, Hessl D, Harris SW, Zhang L, Jardini T, Gane LW, Ferranti J, Ruiz L, Leehey MA, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. American Journal of Human Genetics. 74: 1051-6. PMID 15065016 DOI: 10.1086/420700  1
2004 Zeron MM, Fernandes HB, Krebs C, Shehadeh J, Wellington CL, Leavitt BR, Baimbridge KG, Hayden MR, Raymond LA. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Molecular and Cellular Neurosciences. 25: 469-79. PMID 15033175 DOI: 10.1016/j.mcn.2003.11.014  1
2004 Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, Hook V, Singaraja R, Krajewski S, Goldsmith PC, Ellerby HM, et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death and Differentiation. 11: 424-38. PMID 14713958 DOI: 10.1038/sj.cdd.4401358  1
2004 Zala D, Bensadoun JC, Pereira de Almeida L, Leavitt BR, Gutekunst CA, Aebischer P, Hayden MR, Déglon N. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Experimental Neurology. 185: 26-35. PMID 14697316 DOI: 10.1016/j.expneurol.2003.09.002  1
2003 Li L, Fan M, Icton CD, Chen N, Leavitt BR, Hayden MR, Murphy TH, Raymond LA. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiology of Aging. 24: 1113-21. PMID 14643383 DOI: 10.1016/j.neurobiolaging.2003.04.003  1
2003 Zhang Y, Li M, Drozda M, Chen M, Ren S, Mejia Sanchez RO, Leavitt BR, Cattaneo E, Ferrante RJ, Hayden MR, Friedlander RM. Depletion of wild-type huntingtin in mouse models of neurologic diseases. Journal of Neurochemistry. 87: 101-6. PMID 12969257 DOI: 10.1046/j.1471-4159.2003.01980.x  1
2003 Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T, Rigamonti D, Cattaneo E. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genetics. 35: 76-83. PMID 12881722 DOI: 10.1038/ng1219  1
2003 Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Human Molecular Genetics. 12: 1555-67. PMID 12812983 DOI: 10.1093/hmg/ddg169  1
2003 Wellington CL, Ellerby LM, Leavitt BR, Roy S, Nicholson DW, Hayden MR. Huntington proteolysis in Huntington disease Clinical Neuroscience Research. 3: 129-139. DOI: 10.1016/S1566-2772(03)00055-0  1
2002 Singaraja RR, Hadano S, Metzler M, Givan S, Wellington CL, Warby S, Yanai A, Gutekunst CA, Leavitt BR, Yi H, Fichter K, Gan L, McCutcheon K, Chopra V, Michel J, et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Human Molecular Genetics. 11: 2815-28. PMID 12393793  1
2002 Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 7862-72. PMID 12223539  1
2002 Chan EY, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha JH, Aronin N, Hayden MR, Olson JM. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Human Molecular Genetics. 11: 1939-51. PMID 12165556  1
2002 Ariano MA, Aronin N, Difiglia M, Tagle DA, Sibley DR, Leavitt BR, Hayden MR, Levine MS. Striatal neurochemical changes in transgenic models of Huntington's disease. Journal of Neuroscience Research. 68: 716-29. PMID 12111832 DOI: 10.1002/jnr.10272  1
2002 Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neuroscience. 5: 731-6. PMID 12089530 DOI: 10.1038/nn884  1
2002 Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 33: 849-60. PMID 11906693 DOI: 10.1016/S0896-6273(02)00615-3  1
2002 Gervais FG, Singaraja R, Xanthoudakis S, Gutekunst CA, Leavitt BR, Metzler M, Hackam AS, Tam J, Vaillancourt JP, Houtzager V, Rasper DM, Roy S, Hayden MR, Nicholson DW. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nature Cell Biology. 4: 95-105. PMID 11788820 DOI: 10.1038/ncb735  1
2001 Singaraja RR, Bocher V, James ER, Clee SM, Zhang LH, Leavitt BR, Tan B, Brooks-Wilson A, Kwok A, Bissada N, Yang YZ, Liu G, Tafuri SR, Fievet C, Wellington CL, et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. The Journal of Biological Chemistry. 276: 33969-79. PMID 11423537 DOI: 10.1074/jbc.M102503200  1
2001 Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (New York, N.Y.). 293: 493-8. PMID 11408619 DOI: 10.1126/science.1059581  1
2001 Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, Hayden MR. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. American Journal of Human Genetics. 68: 313-24. PMID 11133364 DOI: 10.1086/318207  1
2000 Wellington CL, Leavitt BR, Hayden MR. Huntington disease: new insights on the role of huntingtin cleavage. Journal of Neural Transmission. Supplementum. 1-17. PMID 11128600  1
2000 Shin JJ, Fricker-Gates RA, Perez FA, Leavitt BR, Zurakowski D, Macklis JD. Transplanted neuroblasts differentiate appropriately into projection neurons with correct neurotransmitter and receptor phenotype in neocortex undergoing targeted projection neuron degeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 7404-16. PMID 11007899  1
2000 Clarke G, Collins RA, Leavitt BR, Andrews DF, Hayden MR, Lumsden CJ, McInnes RR. A one-hit model of cell death in inherited neuronal degenerations. Nature. 406: 195-9. PMID 10910361 DOI: 10.1038/35018098  1
2000 Magavi SS, Leavitt BR, Macklis JD. Induction of neurogenesis in the neocortex of adult mice. Nature. 405: 951-5. PMID 10879536 DOI: 10.1038/35016083  1
2000 Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, Hackam A, Sharp A, Thornberry N, Nicholson DW, Bredesen DE, Hayden MR. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. The Journal of Biological Chemistry. 275: 19831-8. PMID 10770929 DOI: 10.1074/jbc.M001475200  1
1999 Leavitt BR, Wellington CL, Hayden MR. Recent insights into the molecular pathogenesis of Huntington disease. Seminars in Neurology. 19: 385-95. PMID 10716661 DOI: 10.1055/s-2008-1040853  1
1999 Catapano LA, Sheen VL, Leavitt BR, Macklis JD. Differentiation of transplanted neural precursors varies regionally in adults striatum. Neuroreport. 10: 3971-7. PMID 10716243  1
1999 Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 23: 181-92. PMID 10402204 DOI: 10.1016/S0896-6273(00)80764-3  1
1999 Leavitt BR, Hernit-Grant CS, Macklis JD. Mature astrocytes transform into transitional radial glia within adult mouse neocortex that supports directed migration of transplanted immature neurons. Experimental Neurology. 157: 43-57. PMID 10222107 DOI: 10.1006/exnr.1999.6982  1
Show low-probability matches.